lanthanum has been researched along with Hyperparathyroidism, Secondary in 21 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 15 (71.43) | 29.6817 |
| 2010's | 6 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fukagawa, M; Koizumi, M; Komaba, H | 1 |
| Valdivieso, JM | 1 |
| Ben-Dov, IZ; Naveh-Many, T; Nechama, M; Silver, J | 1 |
| De Vos, JY; Elseviers, M | 1 |
| Hutchison, AJ; Mohammed, I | 1 |
| Negi, S; Oda, H; Ohura, M; Sakaguchi, T; Shigematsu, T | 1 |
| Yokoyama, K | 1 |
| Anattiwong, P; Arruda, JA; How, PP; Lau, AH; Mason, DL | 1 |
| Brunner-Ziegler, S; Fröschl, B; Hiebinger, C; Zsifkovits, J | 1 |
| Akizawa, T; Mizobuchi, M; Nakazawa, A | 1 |
| Basterrechea, M; de Arriba, G; Gómez, L; Hernández, B; Pérez, K; Rodríguez-Palomares, JR; Tallón, S | 1 |
| Balducci, A; Coen, G; Curic, S; D'Haese, PC; De Broe, ME; Dimkovic, N; Djukanovic, L; Ferreira, A; Freemont, TJ; Hutchison, A; Pejanovic, S; Popovic, M; Sikole, A; Spasovski, GB; Sulkova, S; Sulowicz, W; Swanepoel, C; Torres, A | 1 |
| Amor, J; Palma, A | 1 |
| Andrés, E; Ballarín, J; Barceló, P; Bover, J; Ortiz-Herbener, F | 1 |
| Finch, J; Liapis, H; Slatopolsky, E | 1 |
| Cunningham, J | 1 |
| Bellinghieri, G; Calò, LA; Monardo, P; Santoro, D; Savica, V | 1 |
| Brancaccio, D; Cozzolino, M | 2 |
| Akizawa, T; Kinugasa, E; Koiwa, F; Ogata, H | 1 |
| Brancaccio, D; Cozzolino, M; Fallabrino, G; Galassi, A; Gallieni, M; Pasho, S | 1 |
12 review(s) available for lanthanum and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis.
Topics: Animals; Binding, Competitive; Bone and Bones; Calcium; Chronic Kidney Disease-Mineral and Bone Disorder; Disease Progression; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Gene Expression Regulation; Glucuronidase; Humans; Hyperparathyroidism, Secondary; Kidney Transplantation; Kidney Tubules; Klotho Proteins; Lanthanum; Models, Biological; Parathyroid Glands; Parathyroid Hormone; Phosphates; Polyamines; Receptor, Fibroblast Growth Factor, Type 1; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency | 2013 |
[Experimental advances in mineral metabolism].
Topics: Animals; Calcinosis; Calcium; Cardiovascular Diseases; Chelating Agents; Chelation Therapy; Chronic Disease; Drug Evaluation, Preclinical; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Intestinal Absorption; Kidney; Kidney Diseases; Lanthanum; Phosphorus; Sodium-Phosphate Cotransporter Proteins | 2008 |
Oral phosphate binders for the management of serum phosphate levels in dialysis patients.
Topics: Acetates; Administration, Oral; Aluminum Hydroxide; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Chelating Agents; Drug Monitoring; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Magnesium; Nephrology; Patient Education as Topic; Phosphorus; Polyamines; Practice Guidelines as Topic; Renal Dialysis; Sevelamer; Treatment Outcome | 2009 |
[Advances in blood purification medicine in 2008].
Topics: Anemia; Hematinics; Hemofiltration; Hepatitis C; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Lanthanum; Plasma Exchange; Practice Guidelines as Topic; Renal Dialysis | 2009 |
[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Paradigm shift in CKD-MBD guideline].
Topics: Bone Density; Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Dialysis; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Practice Guidelines as Topic | 2010 |
[Bone and calcium update; diagnosis and therapy of metabolic bone disease update. Advances in treatment of CKD-MBD].
Topics: Bone Diseases, Metabolic; Chronic Disease; Cinacalcet; Fibroblast Growth Factor-23; Fibroblast Growth Factors; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Klotho Proteins; Lanthanum; Membrane Proteins; Naphthalenes; Vascular Calcification; Vitamin D | 2011 |
[Management of hyperphosphoremia].
Topics: Calcinosis; Calcium; Case Management; Chelating Agents; Chelation Therapy; Epoxy Compounds; Humans; Hyperparathyroidism, Secondary; Iron; Kidney Failure, Chronic; Lanthanum; Phosphorus; Polyamines; Polyethylenes; Sevelamer | 2003 |
[New therapy strategies in secondary hyperparathyroidism on dialysis (I): new concepts, new treatments].
Topics: Algorithms; Bile Acids and Salts; Calcium; Cardiovascular Diseases; Disease Progression; Drug Therapy, Combination; Epoxy Compounds; Female; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Multivariate Analysis; Niacinamide; Phosphate-Binding Proteins; Phosphates; Phosphorus; Polyamines; Polyethylenes; Practice Guidelines as Topic; Randomized Controlled Trials as Topic; Renal Dialysis; Risk Factors; Sevelamer; Time Factors | 2005 |
Phosphate binders and management of hyperphosphataemia in end-stage renal disease.
Topics: Acetates; Aluminum Compounds; Bone Diseases, Metabolic; Calcinosis; Calcium Carbonate; Calcium Compounds; Cardiovascular Diseases; Central Nervous System Diseases; Chronic Kidney Disease-Mineral and Bone Disorder; Diet, Protein-Restricted; Ferric Compounds; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus, Dietary; Polyamines; Renal Dialysis; Sevelamer | 2006 |
Hyperphosphatemia in dialysis patients: the therapeutic role of lanthanum carbonate.
Topics: Chelating Agents; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Phosphates; Phosphorus Metabolism Disorders; Polyamines; Renal Dialysis; Sevelamer | 2007 |
CKD-MBD: impact on management of kidney disease.
Topics: Aniline Compounds; Bone Diseases, Metabolic; Calcium Metabolism Disorders; Cardiovascular Diseases; Chelating Agents; Cinacalcet; Disease Progression; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Naphthalenes; Phenethylamines; Polyamines; Propylamines; Renal Insufficiency, Chronic; Sevelamer; Vitamin D; Vitamin D Deficiency; Vitamins | 2007 |
Preventive measures and new pharmacological approaches of calcium and phosphate disorders.
Topics: Calcium; Chronic Disease; Cinacalcet; Humans; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Naphthalenes; Phosphates; Polyamines; Renal Dialysis; Sevelamer; Vitamin D | 2008 |
1 trial(s) available for lanthanum and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients.
Topics: Adult; Aged; Biomarkers; Bone and Bones; Calcium Carbonate; Chronic Kidney Disease-Mineral and Bone Disorder; Female; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Male; Middle Aged; Phosphates; Renal Dialysis | 2003 |
8 other study(ies) available for lanthanum and Hyperparathyroidism, Secondary
| Article | Year |
|---|---|
Regulation of PTH mRNA stability by the calcimimetic R568 and the phosphorus binder lanthanum carbonate in CKD.
Topics: 3' Untranslated Regions; Adenine; Aniline Compounds; Animals; Calcium; Chronic Disease; Disease Models, Animal; Half-Life; Hyperparathyroidism, Secondary; Kidney Diseases; Lanthanum; Male; Parathyroid Glands; Parathyroid Hormone; Phenethylamines; Phosphates; Phosphorus, Dietary; Propylamines; Rats; RNA Stability; RNA-Binding Proteins; RNA, Messenger; Time Factors; Trans-Activators | 2009 |
The use of phosphate binders: data from contributors to the European Practice Database.
Topics: Acetates; Aluminum Compounds; Analysis of Variance; Calcium Carbonate; Calcium Compounds; Chelating Agents; Cross-Sectional Studies; Databases, Factual; Dietetics; Drug Utilization; Europe; Health Care Surveys; Humans; Hyperparathyroidism, Secondary; Kidney Failure, Chronic; Lanthanum; Nephrology; Polyamines; Practice Patterns, Physicians'; Renal Dialysis; Sevelamer; Surveys and Questionnaires; Vitamin D | 2009 |
Phosphate-binding efficacy of crushed vs. chewed lanthanum carbonate in hemodialysis patients.
Topics: Administration, Oral; Female; Humans; Hyperparathyroidism, Secondary; Lanthanum; Male; Middle Aged; Phosphates; Phosphorus; Renal Dialysis; Tablets | 2011 |
Effectiveness and cost-efficacy of phosphate binders in hemodialysis.
Topics: Adult; Aged; Calcium; Chelating Agents; Chronic Kidney Disease-Mineral and Bone Disorder; Cost Savings; Health Care Costs; Hemodialysis Solutions; Humans; Hypercalcemia; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Parathyroid Hormone; Phosphorus; Polyamines; Renal Dialysis; Renal Insufficiency, Chronic; Sevelamer; Technology Assessment, Biomedical | 2011 |
Lanthanum carbonate and peritoneal catheter dysfunction.
Topics: Catheters; Chelating Agents; Constipation; Equipment Failure; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Kidney Failure, Chronic; Kidney Transplantation; Lanthanum; Male; Middle Aged; Peritoneal Dialysis; Postoperative Complications; Primary Graft Dysfunction; Radiography | 2012 |
Progressive accumulation of lanthanum in the liver of normal and uremic rats.
Topics: Animal Feed; Animals; Creatinine; Female; Femur; Hyperparathyroidism, Secondary; Kidney; Kidney Failure, Chronic; Lanthanum; Liver; Phosphorus; Rats; Rats, Sprague-Dawley; Uremia | 2005 |
The management of secondary hyperparathyroidism.
Topics: Calcium; Cinacalcet; Diet; Humans; Hyperparathyroidism, Secondary; Lanthanum; Naphthalenes; Phosphates; Vitamin D | 2006 |
Clinical consequences and novel therapy of hyperphosphatemia: Lanthanum carbonate for dialysis patients.
Topics: Calcinosis; Chelating Agents; Humans; Hyperparathyroidism, Secondary; Hyperphosphatemia; Lanthanum; Polyamines; Renal Dialysis; Sevelamer; Vascular Diseases | 2007 |